Buscar
Mostrando ítems 1-5 de 5
Artículo
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
(Nature Research, 2021-12-01)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an ...
Artículo
Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy
(MDPI, 2022)
Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival via the release of antigens that reinduce immunocompetence. The biomarkers thus activated may ...
Artículo
Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
(Elsevier Science Ltd, 2022)
Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life ...
Artículo
SEOM clinical guideline for the management of cutaneous melanoma (2020)
(Springer Nature, 2021)
Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to ...
Artículo
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
(American Association for Cancer Research, 2021)
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients ...